SCHOLAR ROCK HOLDING CORPORATION Proceeds from Issuance of Convertible Preferred Stock
SCHOLAR ROCK HOLDING CORPORATION (SRRK) reported Proceeds from Issuance of Convertible Preferred Stock of $46.89 million for the 12-month period ending 2017-12-31, per its 10-K filed 2019-03-19.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2019-03-19
- SCHOLAR ROCK HOLDING CORPORATION proceeds from issuance of convertible preferred stock for fiscal 2017 was $46.89M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|
| 2017-12-31 | $46.89M 10-K · filed 2019-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |